BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 30808814)

  • 1. Cost of Disease Progression in Patients with Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, and Non-Hodgkin's Lymphoma.
    Reyes C; Engel-Nitz NM; DaCosta Byfield S; Ravelo A; Ogale S; Bancroft T; Anderson A; Chen M; Matasar M
    Oncologist; 2019 Sep; 24(9):1219-1228. PubMed ID: 30808814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost of Disease Progression in Patients with Metastatic Breast, Lung, and Colorectal Cancer.
    Reyes C; Engel-Nitz NM; DaCosta Byfield S; Ravelo A; Ogale S; Bancroft T; Anderson A; Chen M; Matasar M
    Oncologist; 2019 Sep; 24(9):1209-1218. PubMed ID: 30796156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time to Next Treatment, Health Care Resource Utilization, and Costs Associated with Ibrutinib Use Among U.S. Veterans with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Real-World Retrospective Analysis.
    Huang Q; Borra S; Li J; Wang L; Shrestha S; Sundaram M; Janjan N
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1266-1275. PubMed ID: 32880204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic and Clinical Burden of Acute Myeloid Leukemia Episodes of Care in the United States: A Retrospective Analysis of a Commercial Payer Database.
    Pandya BJ; Chen CC; Medeiros BC; McGuiness CB; Wilson SD; Walsh EH; Wade RL
    J Manag Care Spec Pharm; 2020 Jul; 26(7):849-859. PubMed ID: 32281456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overall survival, adverse events, and economic burden in patients with chronic lymphocytic leukemia receiving systemic therapy: Real-world evidence from the medicare population.
    Goyal RK; Nagar SP; Kabadi SM; Le H; Davis KL; Kaye JA
    Cancer Med; 2021 Apr; 10(8):2690-2702. PubMed ID: 33734606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Treatment Patterns, Adverse Events, Resource Use, and Costs Among Commercially Insured, Younger Patients with Chronic Lymphocytic Leukemia in the USA: A Retrospective Cohort Study.
    Kabadi SM; Near A; Wada K; Burudpakdee C
    Adv Ther; 2020 Jul; 37(7):3129-3148. PubMed ID: 32399812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic burden of treatment failure in chronic lymphocytic leukemia patients.
    Wang S; Lafeuille MH; Lefebvre P; Romdhani H; Emond B; Senbetta M
    Curr Med Res Opin; 2018 Jun; 34(6):1135-1142. PubMed ID: 29649904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of rituximab-abbs, a biosimilar, and rituximab outcomes in patients with CLL or NHL: A real-world UK study.
    McBride A; Daniel S; Driessen MT; Szende A; Choudhry A; Tian M; Ariely R; Thompson S
    Leuk Res; 2021 Dec; 111():106671. PubMed ID: 34530254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prednimustine and mitoxantrone (PmM) in patients with low-grade malignant non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), and prolymphocytic leukemia (PLL).
    Freund M; Wunsch-Zeddies S; Schäfers M; Wysk J; Seidel I; Hiddemann W; Hanauske AR; Link H; Schmoll HJ; Poliwoda H
    Ann Hematol; 1992 Feb; 64(2):83-7. PubMed ID: 1554799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pigmentary traits, sun exposure, and risk of non-Hodgkin's lymphoma/chronic lymphocytic leukemia: A study within the French E3N prospective cohort.
    Garcin LM; Gelot A; Gomez RR; Gusto G; Boutron-Ruault MC; Kvaskoff M; Severi G; Besson C
    Cancer Med; 2021 Jan; 10(1):297-304. PubMed ID: 33219744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Costs and health care resource utilization among Medicare beneficiaries diagnosed with chronic lymphocytic leukemia.
    Lee TY; Johnson A; Cooke CE; Yared JA; Summers A; Yang K; Liu S; Tang B; Onukwugha E
    J Manag Care Spec Pharm; 2024 May; 30(5):430-440. PubMed ID: 38701030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of white blood cell growth factor use among a large nationwide cohort of elderly non-Hodgkin's lymphoma patients treated with chemotherapy.
    Gruschkus SK; Lairson D; Dunn JK; Risser J; Du XL
    Value Health; 2011; 14(2):253-62. PubMed ID: 21402294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medication Adherence, Health Care Utilization, and Costs Among Patients Initiating Oral Oncolytics for Multiple Myeloma or Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
    Dashputre AA; Gatwood KS; Gatwood J
    J Manag Care Spec Pharm; 2020 Feb; 26(2):186-196. PubMed ID: 32011965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of cutaneous T-cell lymphoma in patients with chronic lymphocytic leukemia and other subtypes of non-Hodgkin lymphoma.
    Chang TW; Weaver AL; Shanafelt TD; Habermann TM; Wriston CC; Cerhan JR; Call TG; Brewer JD
    Int J Dermatol; 2017 Nov; 56(11):1125-1129. PubMed ID: 28685851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melanoma in patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma.
    Famenini S; Martires KJ; Zhou H; Xavier MF; Wu JJ
    J Am Acad Dermatol; 2015 Jan; 72(1):78-84. PubMed ID: 25440434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Costs of introducing autologous BMT in the treatment of lymphoma and acute leukaemia in The Netherlands.
    Uyl-de Groot CA; Okhuijsen SY; Hagenbeek A; Huijgens PC; van Imhoff GW; Löwenberg B; Verdonck LF; Rutten FF
    Bone Marrow Transplant; 1995 Apr; 15(4):605-10. PubMed ID: 7655388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medicare fee-for-service enrollees with primary acute myeloid leukemia: an analysis of treatment patterns, survival, and healthcare resource utilization and costs.
    Meyers J; Yu Y; Kaye JA; Davis KL
    Appl Health Econ Health Policy; 2013 Jun; 11(3):275-86. PubMed ID: 23677706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of hepatitis C virus infection in lymphoproliferative diseases other than B-cell non-Hodgkin's lymphoma, and in myeloproliferative diseases: an Italian Multi-Center case-control study.
    Bianco E; Marcucci F; Mele A; Musto P; Cotichini R; Sanpaolo MG; Iannitto E; De Renzo A; Martino B; Specchia G; Montanaro M; Barbui AM; Nieddu R; Pagano L; Rapicetta M; Franceschi S; Mandelli F; Pulsoni A;
    Haematologica; 2004 Jan; 89(1):70-6. PubMed ID: 14754608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of rasburicase over standard of care for the prevention and treatment of tumor lysis syndrome in children with hematologic malignancies in China.
    Hu S; Han Y; Zhang W; Zhang T; Yao X; Liu L
    J Med Econ; 2019 Aug; 22(8):742-750. PubMed ID: 30939962
    [No Abstract]   [Full Text] [Related]  

  • 20. Medical costs associated with non-Hodgkin's lymphoma in the United States during the first two years of treatment.
    Kutikova L; Bowman L; Chang S; Long SR; Arning M; Crown WH
    Leuk Lymphoma; 2006 Aug; 47(8):1535-44. PubMed ID: 16966264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.